Article
Immunology
Yaping Chen, Yanhui Xiao, Ying Ye, Feng Jiang, Hanqing He, Linyun Luo, Haiping Chen, Lubin Shi, Qiuyue Mu, Wei Chen, Xue Guo, Min Zhang, Jun Li, Qinghu Guan, Zhiping Chen, Xiaoming Yang
Summary: This study demonstrates that in infants, coadministration of an inactivated enterovirus 71 vaccine (EV71 vaccine) with trivalent split-virion inactivated influenza vaccine (IIV3) is safe and does not interfere with immunogenicity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Shengtao Fan, Yun Liao, Guorun Jiang, Lichun Wang, Heng Zhao, Li Yu, Xingli Xu, Dandan Li, Ying Zhang, Qihan Li
Summary: The study developed a bivalent inactivated EV71/CA16 vaccine that, when administered via the intradermal route, activated innate immunity and induced neutralizing antibodies and specific T cellular responses in adult mice. This successful induction of specific protective antiviral immunity suggests that immunization with this vaccine elicits effective immunity against EV71 and CA16 infection.
Article
Public, Environmental & Occupational Health
Lixia Ye, Jieping Chen, Ting Fang, Rui Ma, Jianmei Wang, Xingqiang Pan, Hongjun Dong, Guozhang Xu
Summary: This study investigated the coverage and timeliness of EV71 vaccination among children born in Ningbo, Zhejiang province from 2012 to 2018. Results showed that there is room for improvement in increasing EV71 vaccination coverage and timeliness, especially in addressing disparities among different populations. The study highlights the importance of simultaneous administration in increasing coverage and timeliness of EV71 vaccination.
Article
Immunology
Kanami Tamura, Mai Kohnoe, Ayako Takashino, Kyousuke Kobayashi, Satoshi Koike, Lovkesh Karwal, Shigeru Fukuda, Fue Vang, Subash C. Das, Hansi J. Dean
Summary: The study demonstrates that TAK-021 can provide protection against different sub-genogroups of EV71 in mice, inducing neutralizing antibodies and reducing the risk of viral infection.
Article
Immunology
Jun Gao, Fenyang Tang, Zhiguo Wang, Jing Yu, Ran Hu, Li Liu, Guodong Kang
Summary: This study evaluated the safety profiles of two types of EV71 vaccines administered in Jiangsu Province, China since 2017. A total of 209, 407, and 344 AEFIs cases were reported between 2017 and 2019, with common symptoms including fever, irritability, and allergic eruptions. No significant differences in rare reactions were found between the two types of vaccines.
Article
Immunology
Hongchao Jiang, Zhen Zhang, Qing Rao, Xiaodan Wang, Meifen Wang, Tingyi Du, Jiaolian Tang, Shuying Long, Juan Zhang, Jia Luo, Yue Pan, Junying Chen, Jing Ma, Xiaomei Liu, Mao Fan, Tiesong Zhang, Qiangming Sun
Summary: The use of EV-A71 inactivated vaccine in Kunming City significantly reduced the incidence of EV-A71, while increasing the proportion of non-CV-A16/EV-A71 EVs infections. CV-A6 was identified as the most important causative agent in all clinical symptoms, highlighting the need for developing 4-valent combined vaccines to provide broader protection.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Biochemistry & Molecular Biology
Eun-Je Yi, Young-In Kim, Seung-Yeon Kim, Sung Hyun Ahn, Hyoung Jin Lee, Bohyun Suh, Jaelim Yu, Jeehye Park, Yoon Jung Lee, Eunju Jung, Sun-Young Chang
Summary: Hand-foot-and-mouth disease (HFMD) is a viral infectious disease mainly caused by coxsackievirus (CV) and enterovirus (EV) in children under 5 years old. In the absence of efficient therapeutics, vaccines play a crucial role in preventing HFMD. A bivalent vaccine is needed to provide broad coverage against both CV and EV. This study used Mongolian gerbils as an animal model to investigate the efficacy of a bivalent inactivated EV71 C4a and inactivated CVA16 vaccine. The results showed that the bivalent vaccine induced increased production of Ag-specific IgG antibodies, activated T cell-biased cytokine responses, mitigated paralytic signs, increased survival rate, and decreased viral amplification, indicating its potential as a safe and effective HFMD vaccine candidate.
BIOMOLECULES & THERAPEUTICS
(2023)
Article
Virology
Mei-Qin Liu, Ren-Di Jiang, Jing Guo, Ying Chen, Dong-Sheng Yang, Xi Wang, Hao-Feng Lin, Ang Li, Bei Li, Ben Hu, Ze-Jun Wang, Xing-Lou Yang, Zheng-Li Shi
Summary: This study tested the protective efficacy of the SARS-CoV-2 inactivated vaccine against different spike proteins in SARSr-CoVs. The vaccine provided full protection against one strain and partial protection against another strain. The T-cell response stimulated by the vaccine may explain the cross protection against different SARSr-CoVs. These findings suggest the feasibility of developing pan-sarbecovirus vaccines as preparedness for future outbreaks.
JOURNAL OF VIROLOGY
(2022)
Article
Virology
Amit Raychoudhuri, Anjani Kumari Naru, Sitarami Reddy Kanubothula, Ravali Uddala
Summary: The study demonstrates that formalin inactivated Enterovirus D68 is a promising vaccine candidate that induces high levels of antibodies, with the addition of alum adjuvant enhancing its effectiveness.
Article
Immunology
Noopur Bhatnagar, Ki-Hye Kim, Jeeva Subbiah, Sakinah Muhammad-Worsham, Bo Ryoung Park, Rong Liu, Phillip Grovenstein, Bao-Zhong Wang, Sang-Moo Kang
Summary: The study suggests that heterologous prime-boost influenza vaccination strategy is more effective in inducing broader protective immunity compared to repeated vaccination with the same antigen, by increasing strain-specific hemagglutination inhibition titers and high levels of IgG antibodies.
Article
Immunology
Natalia I. Romanenkova, Thi Thanh Thao Nguyen, Liudmila N. Golitsyna, Natalia V. Ponomareva, Nadezhda R. Rozaeva, Olga I. Kanaeva, Artem V. Leonov, Nadezhda A. Novikova, Maina A. Bichurina
Summary: In South Vietnam, a high proportion of enterovirus 71 (EVA71) was found in cases of hand-foot-and-mouth disease (HFMD), enteroviral meningitis, and acute flaccid paralysis (AFP). The majority of EVA71 belonged to genotype C4, while a smaller percentage belonged to genotype B5. This highlights the importance of surveillance, outbreak prediction, and vaccination to combat EVA71-associated infections.
Article
Immunology
Xiaodong Liu, Shaoying Chang, Ruize Wang, Yanhui Xiao, Fangjun Li, Qing Xu, Shaobai Zhang, Xiao Chen, Shangxiao Zhang, Min Zhang, Xiaoqi Chen, Qingfan Cao, Xiaoyu Liu, Hui Wang, Daihong Zhan, Haiping Chen, Wei Chen, Jianyong Jiang, Chao Zhang, Haijiao Wang, Lidong Gao, Xuanwen Shi, Xiaoming Yang, Aiqiang Xu
Summary: This study investigated the immunogenicity and safety of the enterovirus 71 vaccine. The results showed that simultaneous administration of the vaccine with other vaccines was as effective and safe as separate administration.
Article
Immunology
Eun-Je Yi, Young -In Kim, Jae-Hyoung Song, Hyun-Jeong Ko, Sun -Young Chang
Summary: Mucosal surfaces play a vital role in protecting the body from infection, and mucosal vaccine delivery is crucial for establishing pathogen-specific mucosal immunity. This study investigates the intranasal administration of curdlan and antigen to induce mucosal immune responses and protect against viral infections. The results show that co-administration of curdlan and antigen increases specific antibodies and induces the differentiation of antigen-specific cells. Furthermore, the combination of curdlan and VP1 provides effective protection against enterovirus infection and reduces tissue damage by promoting Th17 responses.
Article
Immunology
Ting Yang, Baofeng Liu, Lei Yue, Tianhong Xie, Hua Li, Mingxiang Shao, Rong Yang, Fangyu Luo, Runxiang Long, Zhongping Xie
Summary: The study showed that the combined inactivated HAV and EV71 vaccine demonstrated good safety profile in animal experiments, with no significant toxicity or adverse reactions observed.
Article
Biochemistry & Molecular Biology
Zi-Wei Ye, Yilan Fan, Kaiming Tang, Chon Phin Ong, Cuiting Luo, Hon-Lam Chung, Tsun-Lam Leong, Ronghui Liang, Wai-Yin Lui, Runhong Zhou, Yun Cheng, Lu Lu, Pak-Hin Hinson Cheung, Jasper Fuk-Woo Chan, Zhiwei Chen, Kwok-Yung Yuen, Shuofeng Yuan, Kelvin Kai-Wang To, Dong-Yan Jin
Summary: Rapid development and successful use of vaccines against SARS-CoV-2 are crucial in curbing the ongoing pandemic of COVID-19. However, vaccine-evasive variants of concern have emerged, posing new challenges to vaccine design and development. This study found that monovalent and bivalent variant-specific inactivated vaccines provide optimal protection against their respective variants, while also showing some cross-variant protection.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2022)
